Stockscreener 앱 받기
114.66
0.95%
-1.10
시장 영업 전:
114.61
-0.05
-0.04%
전일 마감가:
$115.76
열려 있는:
$113.85
하루 거래량:
1.52M
Relative Volume:
0.98
시가총액:
$5.63B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
14.31
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
+8.12%
1개월 성능:
-28.94%
6개월 성능:
-37.04%
1년 성능:
-49.67%
1일 변동 폭
$112.12
$115.25
1주일 범위
$99.80
$116.06
52주 변동 폭
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
114.66 | 5.63B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
424.24 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.14 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
437.44 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
106.28 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.28 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Should Weakness in Charles River Laboratories International, Inc.'s (NYSE:CRL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Cell and Gene Therapy Manufacturing Quality Control Market - openPR.com
Animal Model Market Is Booming Worldwide 2025-2032 | Charles River Laboratories International - openPR.com
Mice Model Market Seeking Excellent Growth | Charles River, Taconic Biosciences, The Jackson Laboratory - openPR.com
High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.
Radiopharmaceutical Preclinical CRO Market With In-Detailed - openPR.com
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - MSN
U.S. Formulation Development Outsourcing Market is Set - openPR.com
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development - Business Wire
Charles River Laboratories Announces Third-Quarter 2024 Results - ADVFN
1,000 monkeys in limbo, some stranded in Frederick, Maryland after shipments from Asia - KFOX
Jefferies Adjusts Price Target on Charles River Laboratories International to $100 From $169, Maintains Hold Rating - marketscreener.com
According to the Latest Report: Dermatology CRO Market - openPR.com
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025 - MSN
20 Mid-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Ecotoxicology Market Detailed in New Research Report By 2032| Charles River Laboratories International - openPR.com
Baird Adjusts Price Target on Charles River Laboratories International to $118 From $101, Keeps Neutral Rating - marketscreener.com
Charles River (CRL) Receives Price Target Boost from Baird Analyst | CRL Stock News - GuruFocus
Charles River (CRL) Receives Price Target Boost from Baird Analy - GuruFocus
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid? - Benzinga
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call | CRL Stock News - GuruFocus
Charles River Labs Earnings: Key Q1 2025 Results Coming May 7What to Watch - Stock Titan
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength? - Yahoo
Charles River (CRL) Price Target Reduced Amid Challenges in Life Sciences Sector | CRL Stock News - GuruFocus
US Stocks Climb With Strong Performances From Real Estate And Utilities - Finimize
US Markets Climb As Sectors Shine With Solid Gains - Finimize
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
TD Cowen Adjusts Charles River Laboratories International's PT to $105 From $179, Keeps Hold Rating - MarketScreener
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Charles River Gets Hit By The FDA, Too Early To Bet On A Comeback - Seeking Alpha
Charles River Faces Significant Regulatory And Macro Pressures (NYSE:CRL) - Seeking Alpha
Charles River (CRL) Faces Uncertainty with FDA's Shift from Animal Testing | CRL Stock News - GuruFocus
Wall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday? - Benzinga
Baird Adjusts PT on Charles River Laboratories International to $101 From $155, Keeps Neutral Rating - MarketScreener
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210 - MarketScreener
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
Charles River (CRL) Faces Uncertainty with FDA's Shift on Animal Testing | CRL Stock News - GuruFocus
FDA's Shift in Testing Requirements Poses Challenge for Charles River (CRL) | CRL Stock News - GuruFocus
Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday? - Insider Monkey
Charles River Laboratories International Inc (CRL) Stock Price D - GuruFocus
Charles River Labs Stock (CRL) Crashes 28% as FDA Signals End of Animal Testing Era - TipRanks
Charles River: Putting FVE Under Review After FDA Announces Plans to Phase Out Animal Testing - Morningstar
Charles River Laboratories (CRL) Faces Impact from FDA's Shift A - GuruFocus
Inotiv and Charles River stock tumble as FDA moves away from animal testing - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Charles River Labs stock tumbles as FDA shifts from animal testing - Investing.com Canada
FDA Shifts Away from Animal Testing, Charles River (CRL) Shares Could Be Impacted | CRL Stock News - GuruFocus
FDA to phase out animal testing requirement, adopt AI methods - Seeking Alpha
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.12%
자본화:
|
볼륨(24시간):